| Werkzame stof | efgartigimod alfa |
| Holder | Argenx Benelux BV |
| Status | Running |
| Indication | Medical Need Program with Vyvgart 1000 mg solution for subcutaneous injection as monotherapy for adult patients with progressive or relapsing active Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), after prior treatment with immunoglobulins and/or corticosteroids. |
| Public documents | Approbation |
| Informed consent | |
| Last update | 29/08/2025 |